13 results
The purpose of the study is to investigate to what extent FE 201836 is tolerated. It will also be investigated how quickly and to what extent FE 201836 is absorbed and eliminated from the body (this is called pharmacokinetics). Also the effect on…
This study aims to collect biochemical evidence for the pro-hemostatic capacity of DDAVP in patients with cirrhosis, in order to proceed towards a more rational clinical use of this drug.
The purpose of the study is to investigate to what extent FE 202217 is tolerated. It will also be investigated how quickly and to what extent FE 202217 is absorbed and eliminated from the body (this is called pharmacokinetics). Also the effect on…
Primary objectives:1) Describe the PD effects on plasma ACTH and serum cortisol upon 100 µg hCRH injection with or without a preceding injection of 10 µg dDAVP 2 hours earlier and study the PK-PD relationship (*Block B*). In particular, the outcome…
This proposal centers on hormone-behavior dynamics in paternal caregiving, with the goal of gaining a better understanding of the development of human paternal caregiving. There is limited information on the hormonal basis of caregiving patterns in…
The aim of this study is to investigate the influence of statin therapy on DDAVP mediated release of VWF and F VIII. We aim to investigate this by measuring F VIII and VWF levels by means of a prolonged DDAVP test prior and after 6 weeks of statin…
The primary objective is to confirm the hypothesis that Maraviroc stimulates immune recovery; the ssecondary objective is to explore, by virologic and immunologic investigations, the underlying mechanisms of this hypothesis.
First, to assess the effect of addition of maraviroc to an abacavir-containing regimen on endothelial function; second, to assess the effect of this intervention on markers of immune activation and chronic inflammation.
Primary Objective:The primary objective of the maraviroc expanded access program is to facilitate access to maraviroc for subjects, who have limited therapeutic options and to collect safety data in a larger and more diverse patient population than…
To show a reduction in FVIII-concentrate consumption with perioperative desmopressin and FVIII concentrate combination treatment compared to FVIII concentrate monotherapy, without decreasing the effectivity of treatment.
1) To evaluate the safety and tolerability of MLT*s npMNAs2) To evaluate the pharmacokinetics of intradermal desmopressin administration via MLT*s npMNAs
To demonstrate the safety, performance and effectiveness of the EMPOWER* Modular Pacing System (MPS), as well as the EMPOWER and EMBLEM* Subcutaneous ICD Coordinated System. Additionally, data from this study may be used to support pre-market and…
To investigate whether on demand dosing using population-based PK-models in VWD patients is reliable and feasible.